Restoration of cytomegalovirus-specific CD4+ T-lymphocyte responses after ganciclovir and highly active antiretroviral therapy in individuals infected with HIV-1 - PubMed (original) (raw)

Restoration of cytomegalovirus-specific CD4+ T-lymphocyte responses after ganciclovir and highly active antiretroviral therapy in individuals infected with HIV-1

K V Komanduri et al. Nat Med. 1998 Aug.

Abstract

Recent studies of subjects infected with human immunodeficiency virus (HIV-1) have produced conflicting results about the extent of reconstitution possible in the CD4+ lymphocyte repertoire after highly active antiretroviral therapy (HAART). The effect of HAART on the incidence of opportunistic infections will probably depend on reconstitution of antigen-specific CD4+ lymphocyte responses to important pathogens, including cytomegalovirus (CMV), the leading cause of blindness in AIDS. Several studies have demonstrated an important role for CD4+ lymphocytes in controlling CMV replication in vitro and in clinical studies. It is now possible to quantitate antigen-specific CD4+ lymphocyte responses by flow cytometry. Using this method, we studied CMV-specific CD4+ lymphocyte responses in individuals infected with HIV-1 with and without a history of active CMV-associated end organ disease (EOD), and in those with quiescent CMV EOD after ganciclovir therapy and HAART. The presence of active CMV-associated EOD strongly correlated with loss of CMV-specific lymphocyte responses (P = 0.0004). In contrast, patients with no history of CMV-associated EOD and most patients with quiescent EOD after HAART demonstrated strong CMV-specific CD4+ lymphocyte responses. These data indicate that the loss of CMV-specific CD4+ lymphocyte responses in individuals infected with HIV-1 who have active CMV EOD may be restored after ganciclovir therapy and HAART, which provides evidence for functional immune reconstitution to an important pathogen.

PubMed Disclaimer

Cited by

HIV Reservoirs and Treatment Strategies toward Curing HIV Infection.
Matsuda K, Maeda K. Matsuda K, et al. Int J Mol Sci. 2024 Feb 23;25(5):2621. doi: 10.3390/ijms25052621. Int J Mol Sci. 2024. PMID: 38473868 Free PMC article. Review.
Ocular Manifestations of Human Immunodeficiency Virus Infection in the Combination Antiretroviral Therapy Era.
Yang M, Kamoi K, Zong Y, Zhang J, Zou Y, Ohno-Matsui K. Yang M, et al. Pathogens. 2023 Dec 4;12(12):1417. doi: 10.3390/pathogens12121417. Pathogens. 2023. PMID: 38133300 Free PMC article.
Cytomegalovirus retinitis and antiretroviral treatment: A fifteen year experience.
Jay Narain S, Visser L, Sibanda W. Jay Narain S, et al. South Afr J HIV Med. 2022 Mar 8;23(1):1322. doi: 10.4102/sajhivmed.v23i1.1322. eCollection 2022. South Afr J HIV Med. 2022. PMID: 35399749 Free PMC article.
Vaccine-elicited CD4 T cells prevent the deletion of antiviral B cells in chronic infection.
Narr K, Ertuna YI, Fallet B, Cornille K, Dimitrova M, Marx AF, Martin K, Abreu Mota T, Künzli M, Schreiner D, Brunner TM, Kreutzfeldt M, Wagner I, Geier F, Bestmann L, Löhning M, Merkler D, King CG, Pinschewer DD. Narr K, et al. Proc Natl Acad Sci U S A. 2021 Nov 16;118(46):e2108157118. doi: 10.1073/pnas.2108157118. Proc Natl Acad Sci U S A. 2021. PMID: 34772811 Free PMC article.
Depletion of Human Papilloma Virus E6- and E7-Oncoprotein-Specific T-Cell Responses in Women Living With HIV.
Mbuya W, Held K, Mcharo RD, Haule A, Mhizde J, Mnkai J, Mahenge A, Mwakatima M, Sembo M, Mwalongo W, Agrea P, Hoelscher M, Maboko L, Saathoff E, Geisenberger O, Rwegoshora F, Torres L, Koup RA, Kroidl A, Chachage M, Geldmacher C. Mbuya W, et al. Front Immunol. 2021 Oct 25;12:742861. doi: 10.3389/fimmu.2021.742861. eCollection 2021. Front Immunol. 2021. PMID: 34759925 Free PMC article.

Restoration of cytomegalovirus-specific CD4+ T-lymphocyte responses after ganciclovir and highly active antiretroviral therapy in individuals infected with HIV-1 - PubMed (original) (raw)